top of page

Dendritic cell therapy -

Ovarian cancer (ovarian carcinoma)

Traditional treatments & modern immunotherapy


Ovarian cancer is one of the most challenging gynecological tumors. Since early symptoms are usually inconspicuous, the diagnosis is often made only in advanced stages.

Successful treatment requires a combination of surgery, chemotherapy, molecular diagnostics, and, if necessary, additional immunological therapy approaches.

This section outlines the classic therapy options as well as dendritic cell therapy (DCT) as a complementary immunological approach.

dendritic cell therapy - ovarian cancer IMMUMEDIC LLC
Flotte

Classic treatment options for ovarian cancer

1. Surgery – a central component of treatment

Surgery is crucial in ovarian cancer, as as much tumor tissue as possible must be removed.

Typical surgical procedures:

  • Removal of the ovaries and fallopian tubes

  • Removal of the uterus, omentum, and affected lymph nodes

  • Peritoneal resection if the tumor has spread

Goal: complete tumor reduction (“debulking”) as far as possible.

​

2. Chemotherapy

Surgery is usually followed by systemic chemotherapy.

Standard regimen:

  • Carboplatin + paclitaxel

It is used adjuvantly or in cases of recurrence and is a central element of therapy.

​

3. Maintenance therapies / targeted therapies

Molecular diagnostics (BRCA1/2, HRD status) play an important role today.

Possible targeted therapies:

PARP inhibitors:

  • Olaparib

  • Niraparib

  • Rucaparib

They are used especially in cases of BRCA mutations or HRD-positive tumors.

​

4. Antibody therapies

Targeted antibodies are used in selected situations:

  • Bevacizumab (VEGF inhibitor)→ inhibits tumor angiogenesis and is often combined with chemotherapy.

  •  

5. Immunotherapy (checkpoint inhibitors)

Its effectiveness in ovarian cancer has been limited so far, but is being intensively researched.

Dendritic cell therapy – an immunological approach to ovarian cancer

Dendritic cell therapy (DCT) is a personalized immunotherapy that aims to activate T cells specifically against tumor cells.

 

DCT procedure

  1. Blood sample taken from the patient

  2. Isolation of monocytes

  3. Cultivation into dendritic cells

  4. Loading with tumor antigens (e.g., tumor lysate)

  5. Maturation into highly active immune cells

  6. Return as an intradermal injection

Dendritic cells present tumor characteristics to the T cells, which can then specifically recognize tumor cells.

DZT as a supplement to conventional cancer therapy

Many patients use dendritic cell therapy as a complementary treatment to strengthen the immune system and supplement a more individualized therapeutic strategy.

​

Possible combinations:

• DCT + chemotherapy

Chemotherapy reduces tumor mass → DCT can support immunological targeting.

​

• DCT + PARP inhibitors

If BRCA/HRD positive → combination can influence the immunological environment.

​

• DZT + antibody therapy (bevacizumab)

Complements angiogenesis inhibition with immunological activation.
 

• DZT + immune-boosting infusions

(e.g., glutathione, resveratrol, selenium, artesunate)

→ Strengthening of the immune system during stressful therapies.

 

Goals of dendritic cell therapy in ovarian cancer

  • Activation of tumor-targeted T cells

  • Support of immune surveillance

  • Supplement to conventional treatments

  • Stabilization of general condition

  • Accompanying option to improve quality of life

Effectiveness is individual and depends on tumor biology and immune status.

Crew

Dendritic cell therapy is a patient-specific immunological approach.

No promises of a cure are made.

Legal Notice

bottom of page